Sintilimab
 | A major contributor to this article appears to have a close connection with its subject. (December 2021) |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-PD-1 monoclonal antibody IBI308[1] |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat
China.[3]
It is a fully
It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical
Side effects
Common side effects include
Research
Currently, more than 20
monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]
References
- ^ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
- ^ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
- Asian Scientist Magazine. January 9, 2019.
- . Retrieved Dec 1, 2018.
- ^ S2CID 59945274.
- SEC.gov. December 20, 2018.
- ^ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019.
- ^ S2CID 58561198.
- ^ A first-in-human phase 1a trial of sintilimab (IBI308). 2018 ASCO Annual Meeting. American Society of Clinical Oncology. 12 October 2019.
- ^ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". PR NewsWire (Press release). Retrieved Feb 22, 2019.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |